Advancing the Development of Targeted, Scalable Cell Therapies Through Disruptive Ex Vivo & In Vivo Technologies, Automated Manufacturing & Strategic Partnerships to Safeguard the Commercial Success of the Industry
The cell therapy field is entering a more demanding phase, with focus shifting from early momentum to long-term commercial success. Attention is turning to novel innovations like in vivo therapies and automated manufacturing: two game-changing strategies that promise to cut costs, speed up development, and unlock commercial viability. With more than $6.6 billion invested in the last six months from the likes of AbbVie and Kite, investor confidence is returning, but with clear expectations. It’s critical to adapt to this next wave of innovation where standout clinical data and scalable platforms are non-negotiable.
The 11th CAR-TCR Summit is your must attend forum, bringing together the latest scientific innovation across therapeutic classes and indications to inform your business strategy and support long term commercial success. Renowned for its caliber of networking and unparalleled depth of content, expect cutting-edge clinical data on ex vivo and in vivo advances, clinical trial strategies to support expanded patient access across indications, scalable and automated manufacturing processes to improve speed and costs, as well as commercial reflections to learn from those on the market.
Built for Depth, Not Dilution:
What Defines This Year's Meeting:
Unmatched Seniority & Unfiltered Perspectives:
With 40% C-suite executives, 55% VPs and directors, VC partners and academic KOLs, gain direct access to the decision makers defining the trajectory of cell therapy, test ideas, refine your pipeline and ignite partnerships.
Unmatched Technical Depth into Cell Therapy Advances:
Beyond access to unpublished preclinical and clinical data, immerse yourself in in-depth technical case studies, understand how the industry’s thought leaders interpret findings and ask critical questions to extract the insights that directly affect your pipeline development.
World’s Most Influential Cell Therapy Community:
With a highly specialized audience of CAR and TCR experts in attendance, this is your opportunity to network with the most prominent stakeholders, build on the lessons of those further ahead and validate your approach to advance your pipeline for 2027 and beyond.
Representation from 70% of the Top Cell Therapy Pharma Companies:
Hear frontline learnings and acquisition strategies from Kite Pharma, Eli Lilly, Regeneron, Novartis, AstraZeneca, Bristol Myers Squibb and Johnson & Johnson across evolving clinical, manufacturing, and licensing developments.
Uniting Scientific Innovation, Manufacturing Scale & Business Strategy:
Uncover the proven development playbook through expert-led deep dives, while connecting with pharma, VC and business development decision-makers to advance your pipeline towards clinical and commercial success.
Attending Companies Include